If you are interested in learning
more about our research program, please call the
VOA Research Department
(757) 466-8683 (Southside) or (757)
873-9833 (Peninsula).
USO 05-033: A Phase I Open Label, Multicenter, Dose-Escalation
Study to Determine the Maximum Tolerated Dose (MTD),
Dose Limiting Toxicity (DLT), Safety and Pharmacokinetics
of CGC-11047 when used in individual combinations with
Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4)
Erlotinib in patients with advanced solid tumors or
lymphoma.
USO 05-125: Phase I Dose-Escalation Study of Seneca
Valley Virus (SVV-001), a Replication-Competent Picornavirus,
in patients with advanced solid tumors with neuroendocrine
features
USO 05-038: A Phase I Trial of Imexon, Injection plus Gemcitabine in advanced, previously untreated pancreatic adenocarcinoma.
USO 05-033: A Phase I Open Label, Multicenter, Dese-Escalation
Study to determine the maximum tolerated dose (MTD),
Dose Limiting Toxicity (DLT), Safety and Pharmacokinetics
of CGC-11047 when used in individual combinations with
1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or
4) Erlotinib in patients with advanced solid tumors
or lymphoma.
USO 05-146: A Phase I Open Label Dose Escalation Study of Continuous Oral Treatment with BIBF 1120 ES Together with Paclitaxel and Carboplatin in patients with advanced stage non-small-cell lung cancer.
USO 05-012: A Phase I, Open-Label, Dose Escalation Study of Weekly Dosing with BB-10901, followed by a phase II Efficacy Expansion.
|
l